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Abstract
Background: The time of infection is rarely known in human cases; thus, the effects of delaying the initiation of antiretroviral
therapy (ART) on the peripheral viral load and the establishment of viral reservoirs are poorly understood.
Methodology/Principal Findings: Six groups of macaques, infected intravenously with SIVmac251, were given placebo or
antiretroviral therapy to explore reservoir establishment; macaques were treated for 2 weeks, with treatment starting 4
hours, 7 or 14 days after infection. Viral replication and dissemination were measured in the gut (rectum), in the lung and in
blood and lymphoid tissues (peripheral lymph nodes), by quantifying viral RNA, DNA and 2LTR circles. We used
immunohistochemistry (CD4 and CD68) to assess the impact of these treatments on the relative amount of virus target cells
in tissue. Treatment that was started 4 hours post-infection (pi) decreased viral replication and dissemination in blood and
tissue samples, which were assessed on day 14 (RNA/DNA/2LTR circles). The virus remained detectable and lymphoid tissues
were activated in LN and the gut in both placebo- and ART-treated animals. Viral RNA in plasma continued to be lower in
macaques treated seven days after infection; however, this was not the case for viral DNA in peripheral blood mononuclear
cells. There was a small but significant difference in RNA and DNA levels in tissues between placebo- and ART-treated
animals on day 21. When started 14 days after infection, treatment resulted in a limited decrease in the plasma viral load.
Conclusions: Treatment that was started 4 hours after infection significantly reduced viral replication and dissemination.
When started 7 days after infection, it was of slight virological benefit in peripheral blood and in tissues, and treatment was
even less effective if started 14 days pi. These data favor starting ART no longer than one week after intravenous SIVmac251
exposure.
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Introduction
Antiretroviral therapy (ART) inhibits viral replication, but does
not eradicate cellular reservoirs of the virus. Recommendations
from the U.S. Department of Health and Human Services on
post-exposure prophylaxis (PEP) favor the use of ART, through
two nucleosidic reverse transcriptase inhibitors (NRTIs) and a
protease inhibitor (PI) or efavirenz for 2-4 weeks, within three days
of exposure to HIV [1]. French guidelines recommend starting
prophylaxis treatment (using two NRTIs plus a PI) within four
hours of exposure (Yeni P. et al., www.sante.gouv.fr [2]). These
recommendations are based on experiments in macaques
challenged with simian immunodeficiency virus (SIV), mimicking
the acute human infection; they suggest a greater benefit for PEP if
initiated within 36 hours, compared with 72 hours after exposure
[3,4]. Nevertheless, being given HIV PEP within the optimal
prescription window is a rare event, as most potentially exposed
patients present 12 hours or even 24 hours after viral exposure
[5]. It is unclear at what point PEP is no longer beneficial, and
there is an absence of data on whether there is a clear benefit to
PEP being initiated more than 48 hours after exposure. The
precise virological and immunological consequences of these
delays are poorly understood and it remains unclear whether
delayed PEP actually leads to better progression of the infection.
Therefore, defining the ideal periods for HIV PEP treatment,
through the study of deep tissues in the macaque model, is a major
concern.
Our main objective was to investigate the impact of ART
treatment start time on viral spread during primary infections. The
combination of AZT-3TC (zidovudine, lamivudine, 4.5 mg/kg,
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(indinavir 60 mg/kg administered per os), administered twice-a-day
for 28 days and started as early as 4 h after IV inoculation with 50
AID50 of SIVmac251, does not prevent infection; however, virus
loads in plasma remained undetectable in most of the animals
during the treatment period [6]. Here, we investigated to which
extent the ART start time affects viral replication and dissemina-
tion during the primary infection.
We therefore evaluated the efficacy of the AZT/3TC/IDV
combination, initiated 4 hours post-infection (pi) or delayed to
before or after the viraemia peak (7 days pi, 14 days pi), on
immunological and virological variables, both in peripheral and
deep compartments. Treatment initiation times were chosen
according to French PEP guidelines (4 hours), periods before
acute CD4+ cell loss [7] and associated with complete protection
in another macaque model [8] (7 days pi), or periods following
CD4+ T cell loss (14 days pi). Previous macaque models infected
intravenously with SIV [4] showed that courses of ART that are
shorter than 28 days confer incomplete protection. We therefore
investigated the effects of administering 2 NRTI plus an unboosted
and weak PI over a 14-day period; the PI selected was a frequently
recommended protease inhibitor at the time of the study in 2004.
This thus allowed an extensive study of viral replication and
dissemination in tissues.
We monitored plasma viral RNA, total viral DNA and 2LTR
circle levels in peripheral blood mononuclear cells (PBMCs),
lymph nodes, rectum and lung, to study viral replication and
dissemination in detail. We studied the effects of infection on viral
target cells (CD4+ T cells or CD68+ macrophages) in tissue
through immuno-histochemistry (IHC), to precisely define the
most effective and the ultimate treatment start time able to reduce
viral dissemination in this model.
Results
Twenty-eight cynomolgus macaques were infected with 50
AID50 of SIVmac251, and were then treated with a placebo, or the
same combination of antiviral drugs described above (AZT, 3TC
and IDV), initiated at 4 hours pi (10 animals, 5 ART-treated, 5
placebo-treated, group H4-D14), on day 7 pi (10 animals, 5 ART-
treated, 5 placebo-treated, group D7-D21) or on day 14 pi (8
animals, 5 ART-treated, 3 placebo-treated, group D14-D28).
Animals were killed 14 days after starting treatment.
Delayed treatment during primary infection remained
beneficial, due to a reduction in the plasma viral load and
the prevention of a significant decrease in circulating
CD4+ T cells
As expected, infection in placebo-treated groups induced a peak
in the plasma viral load and in viral DNA in the PBMCs between
day 13 and 14 (Figure 1A, 1B). CD4 levels in peripheral blood in
these placebo-treated animals were significantly depleted, with the
nadir occurring on day 13 (Median 30% of the baseline,
p=0.0117). This was followed by a rebound to 60–70% of
original levels (Figure 1C) and, in some animals, CD4 levels
returned to base line values on day 28 (not shown). Note that
during the initial acute phase, viral infection induced a significant
decrease in CD8+ T cell counts (down to 5% of baseline values,
p=0.0117); however, in contrast to CD4 T cells, this was followed
by a large early rebound in CD8 T cell counts on day 15 or 17.
Thus, CD8 T cell counts increased to 150% of baseline values
between day 21 and 28 (Figure 1D). This rebound is commonly
associated with immune system activation and the detection of
anti-HIV specific CD8+ cytotoxic T cells [6,9].
The plasma viral load (Figure 1A right, blue line median) and
total SIV DNA in PBMCs were significantly lower (p,0.01) in
animals in which treatment was started 4 hours after infection
than in placebo-treated animals, as previously reported [6,10]
(Figure 1B right, blue line median). Despite significant variability,
circulating CD4+ (908620 cells/mm
3 at day 0 versus
7086537 cells/mm
3 at day 14) and CD8+ T lymphocyte counts
remained relatively stable (mean=7726374 cells/mm
3 at day 0
versus 8576828 cells/mm
3 at day 14; Figure 1C, 1D).
Circulating CD4+ and CD8+ T lymphocyte counts were
significantly higher in PEP-treated animals (4 hr, day 7 and day
14 pi) than in placebo-treated animals (p=0.007 and 0.02,
respectively).
If delayed to 7 days pi, before the viral peak, the treatment,
compared with placebo, exerted a significant impact on SIV RNA
in plasma (p=0.016), but not on SIV DNA in PBMCs
(Figure 1A, 1B, green line). The circulating CD4+ T lymphocyte
level on day 21 pi was not significantly different from that on day 7
(7986393 cells/mm
3 and 7506300 cells/mm
3 respectively). The
CD8+ T lymphocyte count in treated animals (green) was not
significantly greater (10006652 cells/mm
3) on day 21 pi
(Figure 1D). The differences in circulating CD4+ (or CD8+)T
lymphocyte counts between animals treated from day 7 to day 21
(green line) and placebo-treated animals (black line) did not reach
significance.
Treatment of the last group (D14-D28) was started after plasma
viral loads peaked on day 14 pi. Treatment significantly affected
plasma viral load on day 28 (p=0.025), but not SIV DNA in
PBMCs, if compared with placebo (Figure 1A, 1B, red line).
Before treatment, T cell counts of these animals were almost
identical to those in control groups. From day 14, CD4+ cell
counts increased to slightly above the baseline in four of five
animals (Figure 1C, red line). CD8+ T lymphocyte counts did not
significantly differ between day 14 and day 28 (mean 11556658,
and 12926465 cells/mm
3 respectively; p=0.63; Figure 1D, red
line). The differences in circulating CD4+ (or CD8+)T
lymphocyte counts between animals treated 14 days pi and
placebo-treated animals did not reach significance, but a strong
trend was observed in relation to the CD4+ T cell count
(p=0.095).
Impact of antiviral therapy start time on viral replication
and dissemination in deep tissues
We extended our analysis to peripheral lymph nodes (LN) and
mucosal tissues, to determine the spread of the virus more
precisely, based on whether antiviral therapy was administered
early or late. We used a combination of three viral markers – viral
DNA (indicating dissemination), viral RNA (an indicator of viral
replication and production), and 2LTR circles (indicating new
infection) – to study, in detail, viral dissemination and the
dynamics of viral replication in tissues [11]. We showed that early
treatment (4 hours pi) significantly decreased both viral replication
and dissemination for up to 5 level of magnitude compare to
placebo in peripheral LN and mucosal tissues (rectum and lung,
Figure 2). Treatments that were started seven days after infection
continued to impact, although to a lesser extent, both viral
replication and dissemination in peripheral LN and mucosal
tissues (with geometric mean decreases in viral load for all
combined tissues: for SIV RNA, 0.86 log10,p ,0.05, for SIV
DNA, 0.76 log10,p ,0.05, respectively) (Figure 2). Viral
dissemination was lower in mucosal tissues than in LN (p,0.02).
Finally, in the LN, ART that was started on day 14 pi had no
effect on viral replication/dissemination, with SIV RNA/DNA/2-
LTR circles in LN remaining roughly unchanged. In the rectum
ART during SIV Acute Infection
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10570Figure 1. Peripheral viral loads and changes in CD4, and CD8 T cells in placebo- and ART-treated animals. Placebo animals are shown
on the left side (median in dark line), and treated animals, on the right side of the figure. Values for animals are given as a filled symbol and a star
(group H4-D14); open symbol and x (group D7-21); grey symbols and + (group D14-28). Median curves are shown according to the date of treatment
initiation, with the black or dotted line for placebo and blue, green, and red lines for the H4-D14, D7-21 and D14-28 groups, respectively. A) Plasma
viral load; vRNA copies/ml of plasma. B) Total viral DNA in PBMCs; vDNA copies/10
6 PBMC. C) CD4 changes in absolute number (mean6SD) D) CD8
changes in absolute number (mean6SD).
doi:10.1371/journal.pone.0010570.g001
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in SIV DNA (p=0.06), whereas RNA was only detected in one
macaque on day 28 (Figure 2). As in our previous study
(Mannioui et al. [11]), there was a good correlation between the
three markers in the various tissues, similar to that seen in PBMCs.
Impact of antiviral therapy start time on target cells in
deep tissues
The correlation between the level of viral replication in tissues
and the ‘‘in situ’’ depletion of target cells is not well understood
and is often not documented. Thus, we performed IHC in the
peripheral lymph nodes (LN) (Figure 3), rectum (Figure 4) and
lung (Figure 5).
In Lymph nodes (LN) from placebo-treated animals, IHC
performed on day 14 pi showed hypertrophic B follicles
surrounded by large T CD4+ areas localized in the cortex.
Antiviral therapy that was started 4 hr pi did not result in CD4+ T
cell depletion in lymph nodes (Figure 3). Despite a low viral load
in tissues (Figure 2), we found hypertrophic B lymphoid follicles
surrounded by enlarged CD3+ (not shown) and CD4+ T
lymphocyte areas (arrows) in LN (Figure 3). In placebo-treated
animals, a depletion of T CD4+ occurred on day 21, followed by a
partial repopulation on day 28. We observed a progressive
redistribution of CD68+ cells, from the medulla to the germinal
center of follicles localized in cortex, in LN from placebo-treated
animals; this redistribution occurred from day 14 to day 28. If
started before peak viremia (day 7 pi), the treatment did not stop
the depletion of CD4+ T lymphocytes on day 21 (Figure 3), and
did not modify the distribution of CD68+ cells compared to
placebo. Treatment that was started after peak viremia (day 14 pi)
did not modify the level of depletion on day 21, but the slight
preservation of CD4+ T cells in lymph nodes may be explained by
a redistribution of these cells from peripheral blood (Figure 3).
IHC showed an increase in CD3+ (not shown) and CD4+ T
lymphocyte levels in peripheral LN, without reconstitution of the
previous architectural structure (B follicles surrounded by
hypertrophied CD4+ T lymphocyte areas). T zones in LN
occurred in deep areas and were slightly disorganized. In the
same PEP- treated animals, no differences were observed for the
distribution of CD68+ cells.
Depletion in rectal samples in placebo-treated animals (day
14) seemed to occur earlier (Figure 4), with only few CD4+ T
cells found in Peyer’s patches. This early mucosal CD4+ T cell
depletion has been previously described during acute HIV
infection [12]. The initiation of antiviral therapy 4 hours after
infection prevented CD4+ T cell depletion in rectal mucosae
(Figure 4). However, despite a low viral load in tissues of PEP-
treated animals (Figure 2) on day 14, we found hypertrophic B
Figure 2. Change in viral loads in tissues in animals given placebo or treatment over the course of 14 days. Viral loads were expressed
using RNA Log (DCT), DNA and 2LTR Log(Copies/10
6 cells) at the top, middle and at the bottom of the figure, in peripheral LN, rectum, and lung (left
side, middle, and right side), respectively. LN: lymph nodes; placebo animals (Gray bars), treated animals (white bars). Vertical bars represented the
95% confidence interval (95% CI). 2LTR values in the lung were below the threshold and were listed as BT. $ viral RNA was detected in only 1 animal in
ART-treated animals on day 14 and day 28. * Significant differences between placebo and treated animals.
doi:10.1371/journal.pone.0010570.g002
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CD4+ T lymphocyte areas (arrows) in Peyer’s patches in the
rectum (Figure 4). CD4+ T cell depletion was clearly observed on
day 21 in rectal mucosae from placebo-treated animals. Never-
theless, the delayed treatment, which was initiated before the
viremia peak (day 7 pi), did not prevent CD4+ T lymphocyte
depletion on day 21 (Figure 4). Surprisingly, CD4+ T cell
depletion from placebo-treated animals was less pronounced in
day 28 samples; this slight increase may be explained by
redistribution from peripheral blood (Figure 4). CD68+ cells
were found both in Peyer’s patches and intestinal mucosae,
regardless of the time of killing. Depletion of CD4+ T cells in day
14-day 28-treated animals on day 28 seemed greater than that in
placebo-treated animals, whereas the number of CD68+ cells did
not appear to be modified by treatment (see below Figure 6).
In lung samples from placebo-treated animals, the numbers
of T CD4+ cells progressively decreased from day 14 to day 28
(Figure 5). CD68+ cells were identified on day 14, 21, and day
28, with no organized structure. The initiation of antiviral therapy
4 hours after infection prevented CD4+ T cell depletion in lung
tissues (Figure 5). However, despite a low viral load on day 14 in
tissues of treated animals (Figure 2), the number of CD4+ T
lymphocytes was sparse (arrow heads); there were several cells
expressing CD68+ (dotted area) (Figure 5). As expected, CD68+
mononuclear cells remained the predominant leukocyte popula-
tion in the lung, if compared with CD3+ lymphocytes (staining not
shown).
To obtain a more objective view of the changes according to
time of the number of CD4+ and CD68+ cells in the LN and
rectum, we quantified the percentage of the stained area using
large fields (Figure 6). This showed a very distinct pattern of
infection between peripheral LN and mucosal tissues. In placebo
animals (black bars), the percentage of the area that was stained
for CD4+ cells in peripheral LN was very high on day 14 but
decreased on day 21 and day 28. A similar change according to
time was observed for CD68+ cells. CD4+ levels in the rectum
were very low on day 14, but there was a marked increase in the
CD4+ stained area by day 28, whereas the area stained for CD68+
did not change over the course of our study. Analysis of treated
animals (white bars) showed that the effects of treatment in
peripheral LN and the rectum were complex and distinct, and
changed according to tissues and timing. In peripheral LN, the
area stained for CD4+ had not changed by day 14, but CD4+
depletion appeared to be greater on day 21 and 28 despite
Figure 3. Low magnification of IHC stains of peripheral LN samples in placebo- and ART-treated animals. For clarity, we identified the
germinal center (GC), cortex and capsule from a lymph node in one of the panels. The limit of the white pulp region is shown by a dotted line, and
germinal centers are shown using stars. CD4+ staining surrounded lymphoid follicles (black arrows), whereas CD68+ staining was mainly localized in
the white pulp (black arrows) and to a lesser extent in the GC (white arrows). Target cells were shown at the top (CD4+) and the bottom (CD68+)o f
the figure. For each pair of presented animals, placebo-treated animals were located above, and PEP-treated animals below. Animals killed on day 14,
day 21, and day 28 were shown from the left to right of the figure. The horizontal bar on each panel corresponds to 100 mm. Each picture was
representative of explored tissues and was cropped from a large image. Lymph node and GALT architecture organization is shown; specific staining is
colored brown.
doi:10.1371/journal.pone.0010570.g003
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all PEP-treated animals than those treated for placebo at the same
time. Treatment 4 hr after infection appeared to be effective
against early CD4+ T cells depletion in the rectum; this efficiency
was lost when treatment was started later (D7-D21, and
particularly D14-D28). There was no difference in areas stained
for CD68+ between placebo and PEP-treated animals, at
whichever point macaques were studied.
Discussion
We aimed to investigate the impact of either early, or delayed
ART during primary intravenous infection of macaques with
pathogenic SIVmac251. Interestingly, during this period, there is a
clear relationship between peripheral and tissue viral loads both in
placebo and PEP-treated animals for a given date. Our findings
favor the initiation of ART before the viremia peak, even one
week after infection. ART initiated after the peak of viral
replication showed no impact on viral spread, due to early
dissemination.
Very low levels of viral replication (SIV RNA) and dissemina-
tion (DNA) were found in mucosal tissues, if ART was started four
hours after infection (below the threshold in four animals out of 5;
Fig. 2). The immunological benefit of preventing CD4+ T cell
depletion in LN and mucosal tissues is obvious, as for acute
infections: the mucosa is the dominant site of infection, and the
gastrointestinal tract/other mucosal tissues contain at least half of
the body’s T cells [13]. In macaques infected with SIV, intestinal
CD4+ T cells are almost entirely depleted within three weeks of
infection [14–16]. Despite a few studies on the most acute stages of
HIV-1 infection in humans, it is likely that there is a similar large
and rapid loss of intestinal CD4+ T cells during the early periods
of infection [17–19].
ART started seven days after infection continued to have an
impact on both viral replication (RNA) and dissemination (DNA)
in the gastrointestinal tract. Moreover, viral dissemination was
lower in mucosal tissues than in LN. Nevertheless, delayed
treatment did not stop the depletion of CD4+ T lymphocytes in
the rectum, as shown by results on day 21. Verhoeven D et al.,
treating SIV-infected rhesus macaques with PMPA+FTC with the
same schedule (from 7 days pi), reported similar acute CD4+ T cell
loss two weeks after infection in the jejunum [7].
ART that was started 14 days pi did not result in a
significant decrease of SIV DNA and RNA in the rectum.
Macaques treated with PMPA eight weeks after infection have
slightly lower intestinal (samples from jejunum and colon) SIV
RNA levels [20]. Despite a clear activation of the immune
system and modification of lymph-node architecture, which is
typical of this infection [21], CD4+T lymphocyte localization
seemed to be more conserved and the number of CD4+ T
lymphocytes remained higher in treated animals in LN and in
gut associated lymphoid tissues (GALT) than in placebo-
treated animals.
Figure 4. Low magnification of IHC stains of rectal samples in placebo- and ART-treated animals. The lymphoid-rich area (Payer’s patch)
was sectioned by a dotted line and stars indicated lymphoid follicles; rare CD4+ lymphocyte staining is highlighted by arrows. CD68+ staining is seen
in both lymphoid follicles and interstitial zones (arrows). Presentation as in Figure 3.
doi:10.1371/journal.pone.0010570.g004
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contradictory studies using animal models, suggest that there may
be a window of opportunity for initiating ART to preserve
mucosal CD4 T cells or to allow a complete repopulation.
Mehandru et al. found that therapy failed to significantly
repopulate mucosal CD4+ T cells in eight HIV-infected subjects
who started ART early during primary infection [22]. Tincati et
al. evaluated the kinetics of CD4+ T-cell decrease and ART-
mediated immune reconstitution in the gastrointestinal tract of
nine patients during the acute phase of HIV infection, by
performing rectosigmoid colonic biopsies before and after six
months of ART [23]. Time from symptoms to therapy ranged
from 13 to 49 days (mean 26 days) and the regimen most often
used was identical to the one used in this study (AZT+3TC+IDV).
HIV DNA was only marginally reduced in the gastrointestinal
tract; this was associated with persistent immunological impair-
ment in GALT. By contrast, Guadalupe et al. demonstrated that
one patient who started ART within six weeks of infection showed
significant mucosal repopulation [24]. Verhoeven D et al., using
rhesus macaques infected with SIV and treated with FTC
(emtricitabine)/PMPA at 1 weeks of infection over a period of
30 weeks, showed, despite major suppression of viral RNA levels
in GALT, that ART led to a restoration of CD4+T cell levels in
this tissue, in comparison with placebo-treated animals [25,7].
Thus, ART may have been initiated too late, as a severe (and
partially not reversible) depletion of CD4+ T cells in GALT had
already occurred; this contrasts with the rapid and complete
restoration of CD4+ T-cell levels in GALT, which is observed
when the same regimen is initiated one week pi [7]. This
suggestion is supported by a report by George M.D. et al.; they
studied mucosal CD4+T-cell restoration in a model of rhesus
macaques intravenously infected with SIVmac251 and given PMPA
or placebo six weeks after infection, with PMPA given over the
course of 20 weeks [26]. They demonstrated a marked
suppression of mucosal viral loads and rapid reconstitution of
CD4+T cells, in GALT of animals receiving ART. Treatment
initiated one week after infection, using our combination of drugs
(AZT/3TC/IDV) and over a period too short to be fully effective,
reduced viral dissemination, but had no effect on LN hyperplasia.
Despite the impact on viral replication and dissemination in
lymph nodes and mucosal tissues, we were unable to show a clear
benefit toward target cell depletion in these tissues. It may be
related to a lack of potency in the treatment, and/or to the short
duration of the experiment. Previous analysis of B cell
functionality and distribution in these animals on day 14 (early
ART) showed that ART has only a minimal effect on early Ig
production and B cell distribution; however, ART stops the
increase in germinal center growth and other changes observed on
day 28 (D14-28 ART) in mesenteric LN and spleen [27]. Taken
together, these data support a limited but real immunological
benefit associated with ART treatment, even if our understanding
of the underlying mechanisms requires further study.
Figure 5. Low magnification of IHC stains of lung samples in placebo- and ART-treated animals. CD4+ staining was occasionally found in
the lung (arrow). CD68+ (alveolar monocyte/macrophages) staining was greater in the placebo (dotted line) than in ART-treated animals (arrow). A
random portion of the lung was taken from a large image. Presentation as in Figure 3.
doi:10.1371/journal.pone.0010570.g005
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the significance of the number of target cells in animals, as we did
not know the status (resting/activated) of these target cells, and
difficulty in accurately determining the level of viral production,
despite our PCR evaluation. As all the animals were killed, another
limit of our study was the inability to study the natural long-term
outcome of the animals, such as cellular repopulation by target cells
in the various tissues (peripheral lymph nodes, rectum and lung).
The individual virological (reduction of total SIV DNA in
lymphoid organs, despite lack of protection) and public health
(decreasing the infectiousness of HIV in patients with acute HIV-1
infection) benefits of delayed therapy, initiated before the peak of
viremia, even one week after infection, should be taken into account
for persons seeking care 72 hours after HIV exposure. Further
studies should include time points between 48 and 72 hours, a drug
regimen resembling current HIV PEP, and long-term experiments
with or without the cessation of treatment, to study the potential for
long-term change in viral replication patterns and clinical outcome
by stopping or limiting the primary infection [28].
Materials and Methods
Animals and Ethics Statement
Twenty-eight adult Mauritian cynomolgus macaques (Macaca
fascicularis), weighing 4 to 6 kg, were housed in single cages within
level 3 biosafety facilities. They tested negative for SIV, simian T-
lymphotropic virus, herpes B virus, filovirus, simian retrovirus 1,
simian retrovirus 2, measles, hepatitis B virus HBsAg, and hepatitis
B virus HBcAb. Animals were housed and cared for in accordance
with the European guidelines for animal care (‘‘Journal Officiel des
Communaute ´s Europe ´ennes,’’ L358, 18 December 1986). All protocols
used in this study were reviewed and approved by a regional
animal care and use committee: ‘‘Comite ´ Regional d’Ethique sur
l’expe ´rimentation animale Ile de France Sud’’, with the goal of
improving animal welfare and limit suffering. The animals were
sedated with ketamine chlorhydrate (Rhone-Merieux, Lyon,
France), before virus injection, blood sample collection, and
before receiving treatment or placebo, as previously described [6].
Virus inoculation
Macaques were inoculated, via the saphenous vein, using 50% of
the animal intravenous infectious dose (50 AID50) of a cell-free virus
stock of pathogenic SIVmac251 (provided by A. M Aubertin,
Universite ´ Louis Pasteur, Strasbourg, France) in 1 ml of phos-
phate-buffered saline (PBS) [29]. We assessed the in vitro
susceptibility of the virus stock to AZT, 3TC, and indinavir: each
compound, given alone at a concentration of 100 nM, inhibited 56,
76 and 94%, respectively, of SIVmac251 replication in a human
PBMC culture assay, whereas, in combination at 10 and 100 nM,
inhibition reached 93% (10 nM) and was close to 100% (100 nM) in
as i m i l a ra s s a y[ 3 0 ] .
Treatment of animals
Twenty-eight animals were divided into groups of 3 to 5
macaques each, and were given placebo (Fig. 1A) or the
Figure 6. Percentage of the area stained for CD4+ and CD68+ cells (IHC) in peripheral LN and rectum, according to treatment
groups and dates of initiation. Dark dot blots symbolized placebo-treated animals, and white dot blots, PEP-treated animals. The percentage of
the stained area was determined by a quantification performed using two animals per group (see Material and methods).
doi:10.1371/journal.pone.0010570.g006
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subcutaneously, and indinavir (60 mg/kg) orally, using a nasogastric
catheter, twice-a-day [6]. AZT and 3TC were mixed with 9%
sodium saline, to obtain respective concentrations of 4.5 and
2.5 mg/ml; indinavir was mixed with 0.5% methylcellulose, to
obtain a final concentration of 60 mg/ml. The animals received
1 ml/kg of each solution. Treatment was initiated at 4 hours, on
day 7 or on day 14 after infection, and was maintained for 14 days.
The animals being given placebo or ART were then killed on day
14, 21 or day 28.
T-lymphocyte subset determination
PBMCs were analyzed by flow cytometry with a FACScan
cytometer, using CellQuest software (Becton Dickinson), as
described previously [6]. Briefly, we incubated 30 ml of whole blood
for 30 min with anti-CD3 monoclonal antibody (MAb) (FN-18)
(Biosource International, Camarillo, Calif.), anti-CD4 (L200R,
Phycoerythrin (PE)), and anti-CD8 (B9.11; PE-Cyanine 5) mono-
clonal antibodies (BD Biosciences, San Jose, CA, USA). Fluorescein
isothiocyanate (FITC) and PE-conjugated immunoglobulins G1
(Immunotech, Marseille, France) were used as controls.
Plasma viral load determination
Viral RNA was quantified, as previously described [31].
Amplifications were performed in duplicate within an iCycler
thermocycler (Biorad, Marnes-la-Coquette, France). The standard
RNA template dilution, over 7 orders of magnitude, showed a
correlation coefficient of up to 97%, with a sensitivity correspond-
ing to at least 60 copies/ml.
Tissue collection
Peripheral lymph nodes from three locations (axillary, inguinal,
and iliac), lung, (as part of mucosa-associated lymphoid tissue), and
rectum, (as part of the GALT), were collected at necropsy on days
14, 21 and 28 pi. Cell-associated virus loads were then quantified
in these organs, in all animals in the study.
Tissue RNA and DNA extraction
Tissue lysates were obtained after mechanical disruption of
tissue samples in RA1 buffer (Macherey Nagel, Hoerdt, France)
with a Precellys system, using 18 CK tubes with ceramic beads
(Bertin technologies, Montigny-le-Bretonneux, France). The tissue
lysate was then diluted to 30 mg/ml in RA1, aliquoted and stored
at -80uC until extraction. Total RNA was extracted in duplicate
from lysate aliquots using the Nucleospin 96 RNA kit (Macherey
Nagel). Contaminating DNA was removed from RNA samples by
DNA elution and DNase treatment. Total DNA was recovered
from tissue lysates using the Nucleospin 96 tissue kit (Macherey
Nagel), according to manufacturer’s instructions. PBMCs from
non-infected macaques and PBMCs from infected macaques were
used as negative and positive controls, respectively. Quantification
was performed using an external standard, diluted on a log10 scale,
to obtain a standard curve as described [32].
2-LTR circle analysis using real-time PCR
The 2-LTR junction (<274 bp) was amplified in duplicate from
250ng of total DNA in a 25 ml reaction mixture comprising 16
Absolute
TM QPCR SYBH Green Mixes (ABgene, Surrey, UK),
and 400 nM of each primer, REVN1 59-CTCCTGTGCCT-
CATCTGATACA-39 (22 bp) [33] and FMAN 59-TGTGT-
GTTCCCATCTCTCCT-39 (20 bp), which recognizes sequences
in the U5 (nt 158–179) and U3 (nt 10162-10181) regions of
SIVMM239, respectively. PCR cycles included a denaturation
step of 10 min at 95uC followed by 50 cycles of 95uC for 10 s,
61uC for 10 s, and 72uC for 20 s. The copy number of 2-LTR
circles was determined in reference to a standard curve generated
by PCR amplification of a serial dilution of the plasmid
PCR4TOPO2-LTR (containing the SIVmac251 2-LTR junction).
DNA sequence analysis of random samples confirmed that the
PCR products spanned the 2-LTR junction (Figure S1). In our
system (iCycler v3.1, Biorad), we performed linear regression over
the 7-log10-unit range of the 2-LTR circle standard, which
detected up to 20 copies of 2-LTR within 250 ng of cell DNA
(Figure S1) [11].
Viral RNA quantification in tissue
RNA extracted from tissue was analyzed in duplicate by RT-qPCR
using the Super Script III platinum one-step quantitative RT-PCR
system (Invitrogen, Cergy-Pontoise, France) with SIV gag primers and
probe as previously described [34]. Reactions and data acquisition
were carried out with the I-Cycler real-time PCR system (Biorad). To
normalize the RNA input, GAPDH RNA was simultaneously
quantified using a previously published primer set and probe
[35,36]. To determine the amplification efficiency, we included
negative controls and serial 10-fold dilutions of SIV and GAPDH
RNA for each experiment. As the efficiency of each GAPDH and SIV
reaction was similar, we conducted a 2
2DCt analysis. Results were
expressed as SIV RNA copies/GAPDH RNA copies.
Immunohistochemistry (IHC) on paraffin-embedded
tissues
IHC was performed on deparaffinized LN, rectum and lung
sections, after high-temperature antigen retrieval in the presence of
10 mM sodium citrate buffer, pH=6, or 1 mM EDTA pH=9,
with primary mAbs recognizing CD3, CD4 and CD68. Clones,
isotypes, sources, and conditions were 1F6, IgG1, (Novocastra,
Newcastle, UK), pH 9 for CD4; and KP1, IgG1, (Dako, Glostrup,
Denmark), pH 9 for CD68, respectively. Ab binding was visualized
with the StreptABComplex/HRP duet kit and DAB (3,3 Diamino-
benzidine) (Dako). After washing, slides were counterstained with
Mayer’s Hemalun for 45 sec, and were then dehydrated and
mounted. Whole brightfield microscope images (magnification 106
or 46, area 5 to 100 mm2) per sample were captured with a DS-
Ri1 CCD camera mounted on an upright microscope 90i (Nikon
Instrument Europe BV, Amstelveen, The Netherlands).
Quantification of the areas that underwent
immunohistochemical staining
To quantify the percentage of the areas stained for CD4 and CD68,
images were processed and quantified with ImageJ, a public domain
Java image processing program (U.S. NIH). Briefly, brown-colored
images specific for H-DAB stain (red=0.7110272, green=
0.42318153, blue=0.5615672) were extracted by color deconvolution
[37], and measured for specific staining using threshold ImageJ
internal commands. The number of pixels corresponding to CD4 or
CD68 staining and total tissue was obtained, generating the
percentage of the area stained. This percentage, determined using
two fields per animal, was then used for the analysis.
Statistical analysis
Statistical analysis was carried out using nonparametric
Wilcoxon and Mann-Whitney rank tests, which are adapted to
small sample sizes, using StatView software (SAS Institute Inc.,
Cary, N.C). Viral production over the course of a selected period
of time was measured by computing the area under the curve
(AUC) using the trapezoid calculation.
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Figure S1 Scheme of 2 LTR quantification using Q-RT-PCR
and sequences of 2-LTR junction in PCR products cloned into the
plasmid used to provide references curves.
Found at: doi:10.1371/journal.pone.0010570.s001 (2.53 MB TIF)
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